{"id":842327,"date":"2026-10-19T16:28:02","date_gmt":"2026-10-19T16:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=842327"},"modified":"2026-10-19T16:28:02","modified_gmt":"2026-10-19T16:28:02","slug":"epilepsy-market-is-projected-to-boom-by-2036-owing-to-advancements-in-novel-therapies-and-rising-disease-burden-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-is-projected-to-boom-by-2036-owing-to-advancements-in-novel-therapies-and-rising-disease-burden-delveinsight_842327.html","title":{"rendered":"Epilepsy Market is Projected to Boom by 2036 Owing to Advancements in Novel Therapies and Rising Disease Burden | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792341006.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Epilepsy Market is Projected to Boom by 2036 Owing to Advancements in Novel Therapies and Rising Disease Burden | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792341006.jpg\" alt=\"Epilepsy Market is Projected to Boom by 2036 Owing to Advancements in Novel Therapies and Rising Disease Burden | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The epilepsy market is witnessing steady growth, driven by the continuing need for effective seizure control, advancements in antiseizure medications, and the development of innovative therapies for patients with focal-onset seizures and difficult-to-treat epilepsy. Increasing awareness, improvements in diagnosis, and ongoing research into new mechanisms of action are also shaping the treatment landscape.<\/div>\n<p style=\"text-align: justify;\">(Albany, New York) &ndash; October 19, 2026 &ndash; The epilepsy market is witnessing steady growth, driven by the continuing need for effective seizure control, advancements in antiseizure medications, and the development of innovative therapies for patients with focal-onset seizures and difficult-to-treat epilepsy. Increasing awareness, improvements in diagnosis, and ongoing research into new mechanisms of action are also shaping the treatment landscape. According to DelveInsight, the epilepsy market across the seven major markets (7MM)&mdash;the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan&mdash;was valued at approximately USD 9 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of around 7% during 2026&ndash;2036.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s report, &ldquo;Epilepsy &ndash; Market Insight, Epidemiology and Market Forecast &ndash; 2036,&rdquo; provides a comprehensive assessment of the epilepsy market, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market drivers, barriers, and unmet medical needs across the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>Download a sample report:<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Epilepsy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Market growth: The epilepsy market across the 7MM was valued at approximately USD 9 billion in 2023 and is projected to grow at a CAGR of around 7% during 2026&ndash;2036.<\/p>\n<\/li>\n<li>\n<p>Geographic coverage: The report assesses the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.<\/p>\n<\/li>\n<li>\n<p>Disease burden: Epilepsy affects tens of millions of people worldwide and remains a major neurological condition requiring long-term management.<\/p>\n<\/li>\n<li>\n<p>Treatment landscape: Current management relies primarily on antiseizure medications, with additional approaches considered for selected patients whose seizures remain uncontrolled.<\/p>\n<\/li>\n<li>\n<p>Emerging therapies: New mechanisms, including Kv7 potassium-channel modulation, are being investigated to improve seizure control, particularly in focal-onset seizures.<\/p>\n<\/li>\n<li>\n<p>Recent clinical progress: In March 2026, Xenon Pharmaceuticals reported positive topline results from its Phase III X-TOLE2 study of azetukalner in focal-onset seizures.<\/p>\n<\/li>\n<li>\n<p>Competitive landscape: Companies active in the epilepsy treatment market include Neurelis, Biocodex, Aquestive Therapeutics, Ono Pharmaceutical, Biohaven Pharmaceuticals, Xenon Pharmaceuticals, Meda Pharmaceuticals, Autifony Therapeutics, and Greenwich Biosciences, among others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving the Epilepsy Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. High and Continuing Disease Burden<\/strong><\/p>\n<p style=\"text-align: justify;\">Epilepsy is a common chronic neurological disorder characterized by recurrent seizures. Its diverse causes and seizure types create a broad and persistent need for diagnosis, treatment, monitoring, and long-term care. The burden of epilepsy, including its effects on daily functioning, education, employment, and quality of life, supports ongoing demand for effective treatment options.<\/p>\n<p style=\"text-align: justify;\"><strong>2. Need for Better Control of Drug-Resistant Seizures<\/strong><\/p>\n<p style=\"text-align: justify;\">Although several antiseizure medications are available, some patients continue to experience seizures despite treatment. This creates a substantial unmet need for therapies that can improve seizure control, reduce seizure frequency, and potentially offer better tolerability or more convenient administration. Treatment-resistant epilepsy remains an important area of clinical research and commercial opportunity.<\/p>\n<p style=\"text-align: justify;\"><strong>3. Advances in Drug Development<\/strong><\/p>\n<p style=\"text-align: justify;\">Research into new mechanisms of action is expanding the epilepsy treatment pipeline. Kv7 potassium-channel modulators are among the approaches under investigation for focal-onset seizures. Such therapies may offer alternatives to established treatments if clinical development demonstrates meaningful efficacy and an acceptable safety profile.<\/p>\n<p style=\"text-align: justify;\"><strong>4. Innovation in Rescue Treatments and Drug Delivery<\/strong><\/p>\n<p style=\"text-align: justify;\">Seizure clusters can require prompt intervention to reduce the risk of prolonged or repeated seizures. Intranasal rescue therapies offer an alternative to some traditional routes of administration and can support treatment outside hospital settings when used according to prescribing guidance. Product innovation, ease of administration, and caregiver usability remain important considerations in this segment.<\/p>\n<p style=\"text-align: justify;\"><strong>5. Improved Diagnosis and Treatment Personalization<\/strong><\/p>\n<p style=\"text-align: justify;\">Advances in electroencephalography (EEG), neuroimaging, genetic testing, and seizure classification can help clinicians better characterize epilepsy and select appropriate treatment strategies. More accurate identification of epilepsy subtypes and underlying causes may support more individualized care and help identify patients who could benefit from targeted therapies or specialist interventions.<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market: Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The epilepsy market includes established pharmaceutical companies and emerging biotechnology developers working across antiseizure medications, rescue treatments, and investigational therapies.<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies highlighted by DelveInsight include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Neurelis<\/p>\n<\/li>\n<li>\n<p>Biocodex<\/p>\n<\/li>\n<li>\n<p>Aquestive Therapeutics<\/p>\n<\/li>\n<li>\n<p>Ono Pharmaceutical<\/p>\n<\/li>\n<li>\n<p>Biohaven Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Xenon Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Meda Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Autifony Therapeutics<\/p>\n<\/li>\n<li>\n<p>Greenwich Biosciences<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Competition is shaped by the effectiveness and safety of available treatments, seizure-type indications, administration routes, dosing convenience, and the ability to address unmet needs among patients with difficult-to-control seizures. Clinical results and regulatory outcomes for investigational therapies will also influence the future competitive landscape.<\/p>\n<p style=\"text-align: justify;\"><strong>Recent Developments in the Epilepsy Treatment Landscape<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>March 2026: Xenon Pharmaceuticals announced positive topline results from the Phase III X-TOLE2 study evaluating azetukalner in focal-onset seizures. The company stated that it anticipated submitting a New Drug Application to the U.S. Food and Drug Administration in the third quarter of 2026. Regulatory submission and approval status should be checked against the latest company and FDA announcements.<\/p>\n<\/li>\n<li>\n<p>January 2026: Biohaven Pharmaceuticals announced preliminary data from an ongoing open-label extension study of opakalim, a selective Kv7 channel activator, in focal epilepsy. Further pivotal results were anticipated during 2026.<\/p>\n<\/li>\n<li>\n<p>April 2025: Neurelis announced FDA approval of VALTOCO (diazepam nasal spray) for the short-term treatment of seizure clusters, also described as acute repetitive seizures, in patients aged two years and older.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These developments illustrate ongoing activity in both investigational therapies and approved treatment options. Investigational medicines remain subject to clinical evaluation and applicable regulatory review.<\/p>\n<p style=\"text-align: justify;\"><strong>For more information about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Epilepsy Market Insight, Epidemiology and Market Forecast report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>What Is Epilepsy?<\/strong><\/p>\n<p style=\"text-align: justify;\">Epilepsy is a chronic neurological disorder characterized by a tendency to experience recurrent, unprovoked seizures. Seizures occur because of abnormal electrical activity in the brain and can produce changes in awareness, movement, sensation, behavior, or consciousness. The manifestations vary according to the brain regions involved and the type of seizure.<\/p>\n<p style=\"text-align: justify;\">Epilepsy can be classified broadly into focal-onset seizures, generalized-onset seizures, and seizures of unknown onset. Causes may include genetic factors, structural brain abnormalities, infections, traumatic brain injury, stroke, and other neurological or metabolic conditions. In some patients, the underlying cause is not identified.<\/p>\n<p style=\"text-align: justify;\">Diagnosis typically involves clinical history, neurological assessment, EEG, and neuroimaging when indicated. Treatment is individualized according to seizure type, epilepsy syndrome, age, comorbidities, and response to previous medicines. Antiseizure medications are the mainstay of treatment, while selected patients may be considered for surgery, neurostimulation, or dietary therapies. The goal is to achieve the best possible seizure control while minimizing adverse effects and preserving quality of life.<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s epilepsy market report evaluates historical and forecasted epidemiology across the seven major markets. The epidemiological assessment includes:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total prevalent cases of epilepsy<\/p>\n<\/li>\n<li>\n<p>Diagnosed prevalent cases of epilepsy<\/p>\n<\/li>\n<li>\n<p>Gender-specific diagnosed prevalence<\/p>\n<\/li>\n<li>\n<p>Diagnosed prevalence by seizure type in adults<\/p>\n<\/li>\n<li>\n<p>Diagnosed prevalence by seizure type in children<\/p>\n<\/li>\n<li>\n<p>Patient population trends across the United States, EU4 and the United Kingdom, and Japan<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report also examines the distribution of epilepsy by seizure type and relevant associated conditions, helping stakeholders understand patient burden and potential treatment needs across different geographies.<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Epilepsy Market Report<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;Epilepsy &ndash; Market Insight, Epidemiology and Market Forecast &ndash; 2036&rdquo; report provides:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>A detailed overview of epilepsy, including disease background, causes, symptoms, diagnosis, and treatment approaches.<\/p>\n<\/li>\n<li>\n<p>Historical and forecasted epidemiology across the United States, EU4 and the United Kingdom, and Japan.<\/p>\n<\/li>\n<li>\n<p>An assessment of current treatment practices and treatment algorithms.<\/p>\n<\/li>\n<li>\n<p>Analysis of the epilepsy market, including market trends, drivers, barriers, and unmet medical needs.<\/p>\n<\/li>\n<li>\n<p>Review of emerging therapies and the competitive landscape.<\/p>\n<\/li>\n<li>\n<p>Insights to support strategic planning, commercial assessment, and research and development decisions.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For more information about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Epilepsy Market Insight, Epidemiology and Market Forecast report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Forecast Methodology<\/p>\n<\/li>\n<li>\n<p>Epilepsy Market Overview<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview of Epilepsy<\/p>\n<\/li>\n<li>\n<p>Epilepsy Diagnosis and Treatment Algorithm<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population Assessment<\/p>\n<\/li>\n<li>\n<p>Marketed Therapies and Treatment Landscape<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs and Clinical Development<\/p>\n<\/li>\n<li>\n<p>Market Size and Forecast by Geography<\/p>\n<\/li>\n<li>\n<p>Market Drivers and Barriers<\/p>\n<\/li>\n<li>\n<p>Unmet Medical Needs<\/p>\n<\/li>\n<li>\n<p>Competitive Landscape<\/p>\n<\/li>\n<li>\n<p>Key Opinion Leader Insights<\/p>\n<\/li>\n<li>\n<p>Report Methodology<\/p>\n<\/li>\n<li>\n<p>Appendix and Bibliography<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading market research and consulting firm focused on the life sciences and healthcare industries. It provides market intelligence, epidemiology analysis, competitive assessments, and forecasting solutions to help pharmaceutical and biotechnology companies, investors, and other healthcare stakeholders make informed strategic decisions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=epilepsy-market-is-projected-to-boom-by-2036-owing-to-advancements-in-novel-therapies-and-rising-disease-burden-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=epilepsy-market-is-projected-to-boom-by-2036-owing-to-advancements-in-novel-therapies-and-rising-disease-burden-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The epilepsy market is witnessing steady growth, driven by the continuing need for effective seizure control, advancements in antiseizure medications, and the development of innovative therapies for patients with focal-onset seizures and difficult-to-treat epilepsy. Increasing awareness, improvements in diagnosis, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-is-projected-to-boom-by-2036-owing-to-advancements-in-novel-therapies-and-rising-disease-burden-delveinsight_842327.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-842327","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=842327"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842327\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=842327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=842327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=842327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}